作者: Hirohiko TSUJII , Junetsu MIZOE , Tadashi KAMADA , Masayuki BABA , Hiroshi TSUJI
DOI: 10.1269/JRR.48.A1
关键词:
摘要: In 1994 a Phase I/II clinical study on carbon ion radiotherapy was begun at NIRS using HIMAC, which then the world's only heavy accelerator complex dedicated to medical use in hospital environment. Among several types of species, we have chosen ions for cancer therapy because they had most optimal properties terms possessing, both physically and biologically, effective dose-localization body. The purpose investigate efficacy against variety tumors as well develop techniques delivering an efficient dose tumor. RBE estimated be 2.0 3.0 along SOBP acute skin reactions. As August 2006, total 2,867 patients been entered into or II studies analyzed toxicity local tumor response. results shown that has potential ability provide sufficient with acceptable morbidity surrounding normal tissues. Tumors appear respond favorably include locally advanced those histologically non-squamous cell type such adenocarcinoma, adenoid cystic carcinoma, malignant melanoma, hepatoma, bone/soft tissue sarcoma. By taking advantage biological physical high-LET radiation, treatment regimens small fractions short times confirmed almost all radiotherapy.